<DOC>
	<DOCNO>NCT01618916</DOCNO>
	<brief_summary>This phase 1 study otherwise healthy participant high LDL cholesterol . Following multiple dos LY3015014 , safety tolerability drug , body handle drug , drug 's effect body evaluate . Participants participate study approximately 3 month include screen . Screening require within 42 day prior start study .</brief_summary>
	<brief_title>A Study LY3015014 Otherwise Healthy Participants With High Low-density Lipoprotein ( LDL ) Cholesterol</brief_title>
	<detailed_description />
	<criteria>Participants must healthy male female without childbearing potential determined medical history physical examination , include firstgeneration Japanese participant Have body mass index 18 35 kg/m^2 , inclusive , screen Have screen lowdensity lipoprotein cholesterol ( LDLCs ) 100 180 milligram per deciliter ( mg/dL ) , inclusive Have know allergy compound related LY3015014 component formulation know clinically significant hypersensitivity biologic agent Have history atopy , significant allergy humanize monoclonal antibody , clinically significant multiple severe drug allergy , intolerance topical corticosteroid , severe posttreatment hypersensitivity reaction ( include limit erythema multiforme major , linear immunoglobulin [ Ig ] A dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) Have significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug , constitute risk take study medication , interfere interpretation data Have receive vaccine ( ) within 1 month LY3015014 dose intend study Have receive treatment biologic agent ( monoclonal antibody ) within 3 month 5 halflives ( whichever longer ) prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>